Navigation Links
Emergence of recombinant forms of HIV: dynamics and scaling
Date:10/26/2007

The emergence of drug resistant forms of HIV often underlies the failure of current antiretroviral therapies for HIV infection. Specific mutations in the HIV genome confer resistance to individual drugs. Recombination, a process similar to sexual reproduction in higher organisms, can accelerate the accumulation of resistance mutations by mixing the contents of distinct viral genomes and expedite the failure of therapy. The dynamics of the emergence of recombinant forms of HIV in infected individuals remains poorly understood.

In a study publishing in PLoS Computational Biology on October 26, 2007, researchers Suryavanshi and Dixit from the Indian Institute of Science, Bangalore, India present a new model of HIV dynamics that provides a detailed account of the emergence and growth of recombinant forms of HIV following infection with diverse viral genomes. Analysis of experimental data using the model establishes the high rate of HIV recombination and elucidates the origins of scaling relationships that link the relative prevalence of recombinant forms of HIV to the overall extent of infection. The model provides a framework for predicting the development of multi-drug resistance in HIV patients.


'/>"/>

Contact: Johanna Dehlinger
press@plos.org
415-624-1202
Public Library of Science
Source:Eurekalert

Page: 1

Related biology news :

1. Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed
2. Community MRSA is re-emergence of 1950s pandemic, study suggests
3. Treating populations infected with HIV and latent TB could speed the emergence of drug-resistant TB
4. Live Recombinant Adenovirus Vaccine Technique Explored
5. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
6. Products containing specific probes for detecting alternative splice forms protected
7. IBM Transforms the Art of Scientific Expeditions
8. MIT researcher presents new view of how the cortex forms
9. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool
10. New study explores beetle species with two forms of females
11. How the octopus forms an elbow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: